STRATA Skin Sciences Inc (SSKN) was Resumed by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $1.50. Rodman & Renshaw advised their Clients and Investors in a research report released on Feb 21, 2017.
Several company insiders have filed Insider transactions , on Nov 28, 2016, Frank J Mccaney (CEO) purchased 20,000 shares at $0.50 per share price.
STRATA Skin Sciences Inc opened for trading at $0.569 and hit $0.57 on the upside on Friday, eventually ending the session at $0.57, with a gain of 5.56% or 0.03 points. The heightened volatility saw the trading volume jump to 32,592 shares. Company has a market cap of $6.1 M.
Strata Skin Sciences Inc. formerly MELA Sciences Inc. is a medical device company. The Company is engaged in designing and developing software-driven technology for the early detection of skin cancer. The Company operates through three segments: Dermatology Recurring Procedures Dermatology Procedures Equipment and Dermatology Imaging. The Company’s products include the XTRAC laser and VTRAC excimer lamp systems utilized in the treatment of psoriasis vitiligo and various other skin conditions. The Company is focused on the commercialization of its product the MelaFind System (MelaFind). MelaFind is a non-invasive point-of-care instrument to aid in the detection of melanoma. The system features a hand-held component that emits light of multiple wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated algorithms trained by the Company’s database of melanomas and benign lesions.